Curbside Consultation in IBD: 49 Clinical Questions, Second Edition

David T Rubin, MD; Sonia Friedman, MD; Francis A Farraye, MD MSc

Question 15: What Is The Role Of Concomitant Immunomodulators With Biologic Use In Inflammatory Bowel Disease? (continued)

Russell D. Cohen, MD

The introduction of biological therapies as treatment options in patients with inflammatory bowel disease (IBD) in the late 1990s has been a watermark in the quest to control these often difficult relapsing conditions. The initial US Food and Drug Administration (FDA) approval of infliximab was based on data from only 203 Crohn’s disease (CD) patients; as a result, specified subgroups of patients were not large enough to provide meaningful answers to provocative questions regarding issues such as predictors of response and the impact of concomitant immunomodulators (azathioprine…